96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01233960 (ClinicalTrials.gov)	November 29, 2010	2/11/2010	Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease	A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: adult human mesenchymal stem cells	Mesoblast, Inc.	NULL	Completed	18 Years	70 Years	All	73	Phase 3	United States;Australia;New Zealand
2	NCT01510431 (ClinicalTrials.gov)	July 2010	9/1/2012	Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease	An Open-label Compassionate Treatment Protocol to Evaluate the Safety and Treatment Outcomes of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease	Crohn's Disease	Drug: PROCHYMAL (remestemcel-L)	Mesoblast, Inc.	NULL	No longer available	18 Years	70 Years	All			United States
3	NCT00543374 (ClinicalTrials.gov)	September 17, 2007	11/10/2007	Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease	A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: Placebo;Drug: PROCHYMAL adult human mesenchymal stem cells	Mesoblast, Inc.	NULL	Completed	18 Years	70 Years	All	98	Phase 3	United States;Canada
4	NCT00482092 (ClinicalTrials.gov)	September 17, 2007	30/5/2007	Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease	A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: Prochymal ®;Drug: Placebo	Mesoblast, Inc.	NULL	Completed	18 Years	70 Years	All	330	Phase 3	United States;Australia;Canada;New Zealand
5	NCT00294112 (ClinicalTrials.gov)	March 13, 2006	17/2/2006	Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease	A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants	Crohn's Disease	Drug: Prochymal ™ adult human mesenchymal stem cells;Drug: adult human mesenchymal stem cells	Mesoblast, Inc.	NULL	Completed	18 Years	70 Years	All	10	Phase 2	United States